Caricamento...
CYP1A1 and 1B1-mediated metabolic pathways of dolutegravir, an HIV-1 integrase inhibitor
Dolutegravir (DTG), a potent integrase inhibitor, is part of a recommended initial regimen for the treatment of human immunodeficiency virus (HIV). Prior reports demonstrated that the clearance of DTG was higher in current smokers than nonsmokers, but the mechanism remains unclear. Using a metabolom...
Salvato in:
| Pubblicato in: | Biochem Pharmacol |
|---|---|
| Autori principali: | , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6263788/ https://ncbi.nlm.nih.gov/pubmed/30342022 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bcp.2018.10.012 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|